Article Access statistics

Viewed: 308

Emailed: 0

PDF Downloaded: 145

IP International Journal of Ocular Oncology and Oculoplasty


A study on the use of tacrolimus eye oitment (0.03%) in allergic eye disease


Full Text PDF Share on Facebook Share on Twitter


Original Article

Author Details : Vasudha Damle, Prakash Chand Agarwal*

Volume : 5, Issue : 4, Year : 2019

Article Page : 259-263


Suggest article by email

Abstract

Aim: To study the effect of 0.03% tacrolimus eye ointment in allergic eye disease
Materials and Methods: This prospective study was conducted on patients suffering from recurrent
allergic eye disease. All those patients who used steroids frequently because of recurrence or chronic
refractory cases were included in this study. We included 48 cases in this study. Tacrolimus 0.03% eye
ointment was used twice daily for 3 months and effect was seen in terms of improvement in symptoms,
signs and any recurrence if occurred after stopping treatment.
Results: Mean age of the patient was 21.04 7.02 and mean duration of allergic eye disease was 3.52
0.94. Symptoms and sign scores shown improvement after using tacrolimus eye ointment for 3 months.
Itching and redness (88% & 82% respectively) improved dramatically at the end of 1 month. Recurrence
was noticed at 6th month follow up in 6 cases after stopping tacrolimus eye ointment so it was restarted.
While in 42 cases (87.5%) we didn’t notice any recurrence after stopping tacrolimus eye ointment.
Conclusion: Tacrolimus eye ointment (0.03%) is effective in controlling allergic eye disease and is very
effective steroid sparing drug in chronic recurrent cases where frequent use of steroids is required.

Keywords: Allergic eye disease, Vernal keratoconjunctivitis, Perennial allergic conjunctivitis, Immunomodulators & mast cell
stabilizers.


Doi : 10.18231/j.ijooo.2019.059

How to cite : Damle V, Agarwal P C, A study on the use of tacrolimus eye oitment (0.03%) in allergic eye disease. IP Int J Ocul Oncol Oculoplasty 2019;5(4):259-263

Copyright © 2019 by author(s) and IP Int J Ocul Oncol Oculoplasty. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (creativecommons.org)